skip to Main Content

FOLFIRINOX Should Remain Adjuvant Standard for Resectable Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Systemic chemotherapy with FOLFIRINOX should be the backbone of treatment for patients with locally advanced pancreatic cancer who have undergone surgical resection, said Matthew H.G. Katz, MD, FACS.

In results of the phase III PRODIGE 24/CCTG PA.6 trial presented at the 2018 ASCO Annual Meeting, adjuvant mFOLFIRINOX significantly improved overall survival (OS) and progression-free survival (PFS) compared with gemcitabine in patients with metastatic pancreatic cancer. Read more . . .

Back To Top